首页> 外文期刊>Applied Organometallic Chemistry >Neutral and cationic half-sandwich arene d(6) metal complexes containing pyridyl and pyrimidyl thiourea ligands with interesting bonding modes: Synthesis, structural and anti-cancer studies
【24h】

Neutral and cationic half-sandwich arene d(6) metal complexes containing pyridyl and pyrimidyl thiourea ligands with interesting bonding modes: Synthesis, structural and anti-cancer studies

机译:中性和阳离子半三明治芳烃D(6)金属配合物,含有吡啶基和嘧啶基的配体,具有有趣的粘合模式:合成,结构和抗癌研究

获取原文
获取原文并翻译 | 示例
           

摘要

The reaction of [(p-cymene)RuCl2](2) and [Cp*MCl2](2) (M = Rh/lr) with benzoyl (2-pyrimidyl) thiourea (L1) and benzoyl (4-picolyl) thiourea (L2) led to the formation of cationic complexes bearing formula [(arene) M (L1)kappa Cl-2((N,S))](+) and [(arene) M (L2)kappa(2)(N,s)Cl](+) [(arene) = p-cymene, M = Ru, (1, 4); Cp*, M = Rh (2, 5) and Ir (3, 6)]. Precursor compounds reacted with benzoyl (6-picolyl) thiourea (L3) affording neutral complexes having formula [(arene) M (L3)kappa Cl-1((s))2] [arene = p-cymene, M = Ru, (7); Cp*, M = Rh (8), Ir (9)]. X-ray studies revealed that the methyl substituent attached to the pyridine ring in ligands L2 and L3 affects its coordination mode. When methyl group is at the para position of the pyridine ring (L2), the ligand coordinated metal in a bidentate chelating N, S- mode whereas methyl group at ortho position (L3), it coordinated in a monodentate mode. Further the anti-cancer studies of the thiourea derivatives and its complexes carried out against HCT-116, HT-29 (human colorectal cancer), Mia-PaCa-2 (human pancreatic cancer) and ARPE-19 (non-cancer retinal epithelium) cell lines showed that the thiourea ligands are inactive but upon complexation, the metal compounds displayed potent and selective activity against cancer cells in vitro. Iridium complexes were found to be more potent as compared to ruthenium and rhodium complexes.
机译:[(p-cyheyene)rucl2](2)和[Cp * Mcl 2](2)(m = Rh / Lr)与苯甲酰(2-嘧啶)硫脲(L1)和苯甲酰基(4-吡啶基)硫脲( L2)导致亚静态复合物的形成轴承式[(芳烃)M(L1)Kappa Cl-2((N,S))](+)和[(arene)m(l2)κ(n)(n, S)Cl](+)[(arene)= p-cymene,m = ru,(1,4); CP *,M = RH(2,5)和IR(3,6)]。前体化合物与苯甲酰(6-吡酰基)硫脲(L3)反应,得到中性配合物,其具有式[(芳烃)M(L3)Kappa Cl-1((S))2] [arene = p-cymene,m = Ru,( 7); CP *,M = RH(8),IR(9)]。 X射线研究表明,连接在配体L2和L3中的吡啶环上的甲基取代基影响其协调模式。当甲基处于吡啶环(L2)的对位置时,在双齿螯合N,S-模式下的配体配位金属,而在邻位置(L3)处的甲基,其在单齿模式中配功。进一步进一步对硫脲衍生物的抗癌研究及其复合物对HCT-116,HT-29(人结肠癌),MIA-PACA-2(人胰腺癌)和ARPE-19(非癌症视网膜上皮)进行细胞系表明,硫脲配体是无活性的,但在络合物后,金属化合物在体外显示抗癌细胞的有效性和选择性活性。发现铱络合物与钌和铑配合物相比,更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号